Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Regular Articles

A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Rofecoxib, a Selective Cyclooxygenase-2 Inhibitor, on Rectal Polyps in Familial Adenomatous Polyposis Patients

Tetsuro Higuchi, Takeo Iwama, Keigo Yoshinaga, Masahiro Toyooka, Makoto M. Taketo and Kenichi Sugihara
Tetsuro Higuchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeo Iwama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keigo Yoshinaga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Toyooka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makoto M. Taketo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenichi Sugihara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: The aim of this study was to examine the effect of a specific cyclooxygenase-2 inhibitor, rofecoxib, on rectal polyps in familial adenomatous polyposis patients.

Experimental Design: This was a randomized, double-blind, placebo-controlled study of the efficacy and safety of rofecoxib in the rectum. Initially, 21 patients were assigned randomly in a 1:1 ratio to receive either 25 mg rofecoxib once a day or a placebo p.o. for 9 months. Patients underwent endoscopy at the beginning of the study and then every 3 months thereafter. We reviewed the videotapes to measure the number and size of polyps in the same area throughout the study period in each individual patient.

Results: The polyp number, measured as the percentage of change from the baseline values, was significantly decreased in the rofecoxib group at 3, 6, and 9 months. At 9 months, the polyp number in the rofecoxib group decreased by 6.8% from the baseline values, whereas that in the placebo group increased by 3.1%. The 9.9% difference between the rofecoxib and placebo groups was statistically significant (P = 0.004). At 9 months, the rofecoxib group showed a significant reduction from the baseline in polyp size as compared with the placebo group (−16.2% versus 1.5%; P < 0.001). There was no statistically significant increase in the incidence of any adverse events in treatment with rofecoxib compared with placebo (P = 0.922).

Conclusions: In this study, once-daily treatment with 25 mg rofecoxib, a cyclooxygenase 2-specific inhibitor, significantly decreased the number and size of rectal polyps in familial adenomatous polyposis patients.

INTRODUCTION

FAP2 is an autosomal dominant disease caused by a germ-line mutation in the APC gene located at chromosome 5q21 (1, 2, 3) . Patients with FAP develop hundreds to thousands of adenomatous polyps, and they are at a nearly 100% risk of colorectal cancer (4) . Management includes prophylactic proctocolectomy or colectomy followed by sigmoidoscopic surveillance and rectal polypectomy. Studies of FAP may contribute to the prevention of colorectal cancer in patients with not only in FAP but also sporadic polyps.

Epidemiological studies have shown that regular use of aspirin-like drugs or NSAIDs reduces the incidence of and mortality from sporadic adenoma and colorectal cancer (5, 6, 7) . Recent studies in two large randomized, double-blind clinical trials have demonstrated that aspirin reduces the risk of recurrent adenomas among patients with a history of colorectal cancer or adenomas (8 , 9) . There are case reports indicating that adenomatous polyps may regress in FAP patients who receive sulindac, an NSAID (10 , 11) . In small, randomized, placebo-controlled trials, sulindac treatment produced a significant regression of colorectal adenomas in patients with FAP (12, 13, 14) . However, long-term use of conventional NSAIDs for cancer prevention is hampered by their strong gastrointestinal toxicity (15) . In FAP, the chemopreventive effects of NSAIDs appear to be through their inhibition of COX-2 (16 , 17) . A COX-2-selective inhibitor, celecoxib, has been shown to decrease polyp number and size in chemically induced Apc mutant Min mouse (18) . In a clinical trial with FAP patients, celecoxib has also been reported to have moderate efficacy in reduction of colonic polyps, at twice the maximum recommended dose for patients with osteoarthritis and rheumatoid arthritis (19) . Rofecoxib is a COX-2-specific inhibitor, which has higher selectivity to COX-2 than celecoxib (20) . In vivo, rofecoxib has been shown to reduce polyp number and size in the Apc mutant mouse; hence, rofecoxib is a potential chemopreventive agent in adenoma and colon cancer (21) . The aim of this study was to examine the effect of rofecoxib at a clinically approved dose in the United States and Europe on rectal polyps in FAP patients.

MATERIALS AND METHODS

Patients.

This was a randomized, double-blind, placebo-controlled study of the efficacy and safety of rofecoxib in reducing percentage area of disease in the rectum, and in reducing the extent of rectal polyposis. Twenty-one patients with FAP were enrolled in the study (11 males and 10 females, median age 30 years), recruited during their routine clinical follow-up at Kyoundo Hospital Sasaki Institute, (Tokyo, Japan) and Tokyo Medical and Dental University. Patients diagnosed as FAP on the basis of having at least 100 colorectal polyps at endoscopy and/or in colectomy specimens were eligible if they had five or more rectal polyps of ≥2 mm in diameter when assessed endoscopically, and if the rectal region was still intact. Accordingly, patients with attenuated FAP were not included. The age distribution of enrolled patients was 19–55 years. No patients were tested for APC mutations. Subjects included 13 postcolectomy patients. Although average time postcolectomy was 87 months, we did not exclude patients within 2 years after operations.

The following were the reasons for exclusion from the study: patients required colectomy for dense adenomas, had >10-mm adenoma or malignant disease, use of an NSAID or aspirin within 1 month preceding the study, history of peptic ulcers or gastrointestinal hemorrhage, history of severe side-effects by NSAIDs, clinically significant abnormal results in laboratory data, history of active bacterial infection, drug hypersensitivity, absence of the use of effective birth control in women of childbearing age, or pregnancy.

The study was approved by the Institutional Review Boards of the investigative sites, and written informed consent was obtained from all of the patients. Because rofecoxib is not yet approved for clinical use in Japan, the protocol was submitted to and approved by Japanese Ministry of Health and Welfare. According to the protocol, 21 patients were initially assigned randomly in a 1:1 ratio to receive p.o. either 25 mg rofecoxib (Merck and Co., Inc.) or an identical-appearing placebo once daily for 9 months. The rofecoxib dose of 25 mg was selected on the basis of the standard therapy for osteoarthritis. The study was double-blind: treatment assignments were not revealed to any patients, investigators, or endoscopists until the drug treatment was completed and clinical data were collected. Patients ambulated to the study center monthly to be assessed for the compliance and safety. Adverse effects were also monitored monthly on their visits. Laboratory tests were performed before the start of the study (at the baseline), and after 1, 2, 3, 4, 6, 9, and 10 months during the study. The study schedule is shown in Table 1⇓ . Before the blind code was opened, 5 patients were excluded from the efficacy analysis, although they were included in the safety analysis. Namely, 21 patients were included in the safety analysis, and 16 patients were included in the efficacy analysis. The following are reasons for 5 patients excluded from the efficacy analysis. One patient had no available endoscopic data before (at the baseline) the treatment, 1 had a history of total gastrectomy (difficult to evaluate the efficacy because of potential effects on drug absorption), 1 had used another NSAID for a treatment of an adverse effect, 1 discontinued within a month because of an adverse effect (gastroenteritis), and another requested to discontinue the drug treatment because of adverse effect (redness of legs and gingival pain).

View this table:
  • View inline
  • View popup
Table 1

Schedule of the study

Endoscopy.

Videotaped colonoscopy with Olympus flexible colonoscopes was performed before the beginning of the study therapy (the baseline), every 3 months during the treatment, and at 3 months after the treatment. An intestinal enema was given as a pretreatment with 200–500 ml saline solution. The indigocarmine spraying method was used during the endoscopy so that no small or flat adenomas were overlooked. At the baseline endoscopy, the largest rectal polyp was identified as a landmark, and the diameters of this polyp as well as four more vicinal polyps were determined using the endoscopic ruler. The endoscopic examinations were videotaped, and a series of photographs were taken of the area near the landmark polyp. These photographs were used for quantitative measurements of the number and size of polyps. Follow-up gastroduodenoscopic examinations were performed at the baseline, 9 months, and 12 months, respectively.

Clinical Assessment.

For each patient, the same investigator who performed the endoscopy reviewed the videotapes and prepared the video-photographs of polyps of the same area for evaluation throughout the study period. Independent endoscopists assessed the number and size of polyps based on these video-photographs. The efficacy of the treatment was assessed by separate investigators from those who performed the endoscopy or prepared the video-photographs.

Statistical Analysis.

The number and average size of polyps were compared between the treatment groups using a covariance analysis model with factors for treatment and baseline as a covariate. The data were log-transformed for the analysis using the log values at month 9/at baseline, and the results were back-transformed to percentage changes from the baseline scale. For data from missing patients, their last observed values before the missing time point were carried forward for the purpose of plotting the mean values.

RESULTS

Demographic Characteristics.

Twenty-one patients were enrolled: 14 at Kyoundo Hospital and 7 at Tokyo Medical and Dental University. There were no significant clinical differences in patient demographic characteristics between the treatment groups (Table 2)⇓ .

View this table:
  • View inline
  • View popup
Table 2

Baseline characteristics of the patients with familial adenomatous polyposisa

Response to Treatment.

The number of polyps, measured as the percentage of change from the baseline values, was significantly decreased in the group given rofecoxib at 3, 6, and 9 months (Fig. 1)⇓ . At 9 months, the polyp number in the group given rofecoxib decreased by 6.8% from the baseline values, whereas in the group of placebo, it increased by 3.1%. The 9.9% difference between the rofecoxib and placebo groups was statistically significant (P = 0.004). Similar decreases were found in the polyp size (Fig. 2)⇓ . At 9 months, the group given rofecoxib was associated with a significant reduction from the baseline in the size of rectal polyps as compared with the placebo group (−16.2% versus 1.5%; P < 0.001). At 3 months after completion of rofecoxib treatment, the slight relapse of rectal polyps was seen. No patient showed complete disappearance of the polyps. Nine patients (5 in rofecoxib group and 4 in placebo group) had duodenal polyps at the baseline. There were no obvious changes found in any of the patients before breaking the code; therefore, we decided not to analyze the duodenal polyps.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Mean percentage of change from base line in the number of polyps; bars, ±SE. At 9 months, the polyp number in the group given rofecoxib decreased by 6.8% from the baseline values, whereas in the group of placebo, it increased by 3.1%. The 9.9% difference between the rofecoxib and placebo groups was statistically significant (P = 0.004).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Mean percentage of change from base line in the size of polyps; bars, ±SE. At 9 months, the group given rofecoxib was associated with a significant reduction from the baseline in the size of rectal polyps as compared with the placebo group (−16.2% versus 1.5%; P < 0.001).

Safety.

Rofecoxib was well tolerated. The most common adverse effects were stomatitis and abdominal pain. One patient (8.3%) of 12 in the rofecoxib group reported a serious adverse effect, but none of 9 patients in the placebo group did. Namely, a patient in the rofecoxib group had gastroenteritis with several clinical symptoms (watery diarrhea, right lower quadrant pain, and general fatigue). The study drug was discontinued, and gastroenteritis disappeared. There was no statistically significant difference in the incidence of any adverse effects between the two groups (P = 0.922). No ulceration was observed in any patients on the follow-up gastroduodenoscopy. No peripheral edema was found in any patients. Likewise, there were no significant changes in blood pressure in the patients of either group. There were also no clinically significant changes in the laboratory test results such as complete blood count, serum proteins, transaminases, alkaline phosphate, lactate dehydrogenase, blood urea nitrogen, creatinine, uric acid, electrolytes or iron, or in urinalysis data.

DISCUSSION

In this randomized, double-blind, placebo-controlled study, we have demonstrated that rofecoxib at 25 mg is effective in reducing the number and size of rectal polyps in FAP patients. Accumulating evidence indicates that COX-2 plays an important role in colorectal tumorigenesis. The present clinical findings are consistent with recent animal data that COX-2 inhibitor rofecoxib can suppress intestinal polyposis (21) . It was reported earlier that the proinflammatory, pro-oncogenic protein COX-2 is markedly induced in the ApcΔ716 polyps at an early stage of polyp development, and that inhibition of COX-2 in the ApcΔ716 mouse, either by gene knockout or by specific inhibitors, can suppress intestinal polyposis (16 , 17 , 22) . These results opened the possibility that specific COX-2 inhibitors such as celecoxib and rofecoxib could be effective chemopreventive agents for human colon polyposis and cancer. In fact, celecoxib has been demonstrated to be effective in reducing the number and size of colonic polyps in FAP patients (19) . Our results are consistent with those with celecoxib, although we have focused on the effects of rofecoxib on rectal polyps.

The major purpose of our study has been to evaluate the chemopreventive effects of a COX-2 inhibitor that could serve as an adjuvant therapy after subtotal colectomy. Proctocolectomy with ileoanal anastomosis has been accepted as the standard operation for FAP patients. However, the operation requires extremely complex procedures, and has a high incidence of postoperative complications, compared with colectomy with an ileorectal anastomosis. Moreover, this radical operation affects the stool habit of the patients and compromises their quality of life. If the patients are younger, it can even affect their psychological development. Because of these reasons, colectomy with ileorectal anastomosis is a preferable operation giving a satisfactory functional result. To monitor the possible development of rectal carcinoma after surgery, it is important to continue periodic follow-up of the remaining rectum (23) .

The possible use of rofecoxib to control the remaining rectal polyps in FAP patients was the motivation for this study. Long-term use of rofecoxib is well tolerated and provided efficacy that is comparable with that of a conventional NSAID in osteoarthritis (24) . A large study demonstrated that rofecoxib is associated with significantly fewer clinically important upper gastrointestinal side effects than conventional NSAIDs (25) . In the current study, the maximum reduction in the number of polyps was observed after 9 months of treatment with rofecoxib, whereas the slight relapse of rectal polyps was seen 3 months after completion of the rofecoxib treatment. It is important to note that no severe side effects were reported during the 9-month treatment period.

In conclusion, we have demonstrated that COX-2-specific inhibitors, such as rofecoxib, can help suppress the progression of colorectal polyps in FAP patients. If it is possible to prevent the development of rectal polyps and their progression to malignancy with chemotherapy with COX-2 inhibitors, then clearly the clinical benefits to patients with FAP would be considerable. Our data, although limited to the assessment of the polyps in the rectum, are encouraging and open the possibility of this adjuvant therapy for many patients with FAP.

Acknowledgments

We thank Satoko Sasaki, Seiichi Okamoto, Keisuke Nakamura, Kimihiko Sato, and Dr. Tadaaki Taniguchi of Banyu Pharmaceutical Co., Tokyo, Japan, for excellent technical support.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 To whom requests for reprints should be addressed, at Department of Digestive Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. Phone: 81-3-5803-5261; Fax: 81-3-5803-0139; E-mail: k-sugi.srg2{at}tmd.ac.jp

  • ↵2 The abbreviations used are: FAP, familial adenomatous polyposis; APC, adenomatous polyposis coli; NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase.

  • Received February 17, 2003.
  • Revision received June 10, 2003.
  • Accepted June 24, 2003.

References

  1. ↵
    Nishisho I., Nakamura Y., Miyoshi Y., Miki Y., Ando H., Horii A., Koyama K., Utsunomiya J., Baba S., Hedge P., Markham A., Krush A. J., Petersen G., Hamilton S. R., Nilbert M. C., Levy D. B., Bryan T. M., Preisinger A. C., Smith K. J., Su L-K., Kinzler K. W., Volgelstein B. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science (Wash. DC), 253: 665-669, 1991.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Kinzler K. W., Nilbert M. C., Su L-K., Volgelstein B., Bryan T. M., Levy D. B., Smith K. J., Preisinger A. C., Hedge P., McKechnie D., Finniear R., Markham A., Groffen J., Boguski M. S., Altschul S. F., Horii A., Ando H., Miyoshi Y., Miki Y., Nishisho I., Nakamura Y. Identification of FAP locus genes from chromosome 5q21. Science (Wash. DC), 253: 661-665, 1991.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Groden J., Thliveris A., Samowitz W., Carison M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M., Sargeant L., Krapcho K., Wolff E., Burt R., Hughes J. P., Warrington J., McPherson J., Wasmuth J., Le Paslier D., Abderrahim H., Cohen D., Leppert M., White R. Identification and characterization of the familial adenomatous polyposis coli gene. Cell, 66: 589-600, 1991.
    OpenUrlCrossRefPubMed
  4. ↵
    Bussey H. J. R. . Familial Polyposis Coli: Family Studies, Histopathology, Differential Diagnosis, and Results of Treatment., Johns Hopkins University Press Baltimore 1975.
  5. ↵
    Thun M. J., Namboodiri M. M., Heath C. W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
    OpenUrlCrossRefPubMed
  6. ↵
    Rosenberg L., Palmer J. R., Zauber A. G., Warshauer M. E., Stolley P. D., Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduced the incidence of large-bowel cancer. J. Natl. Cancer Inst., 83: 355-358, 1991.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Giovannucci E., Rimm E. B., Stampfer M. J., Colditz G. A., Ascherio A., Willett W. C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med., 121: 241-246, 1994.
    OpenUrlCrossRefPubMed
  8. ↵
    Sandler R. S., Halabi S., Baron J. A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J. M., Karp D. D., Loprinzi C. L., Steinbach G., Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med., 348: 883-890, 2003.
    OpenUrlCrossRefPubMed
  9. ↵
    Baron J. A., Cole B. F., Sandler R. S., Haile R. W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R. W., Rothstein R., Burke C. A., Snover D. C., Church T. R., Allen J. I., Beach M., Beck G. J., Bond J. H., Byers T., Greenberg E. R., Mandel J. S., Marcon N., Mott L. A., Pearson L., Saibil F., van Stolk R. U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348: 891-899, 2003.
    OpenUrlCrossRefPubMed
  10. ↵
    Waddell W. R., Loughry R. W. Sulindac for polyposis of the colon. J. Surg. Oncol., 24: 83-87, 1983.
    OpenUrlCrossRefPubMed
  11. ↵
    Waddell W. R., Ganser G. F., Cerise E. J., Loughry R. W. Sulindac for polyposis of the colon. Am. J. Surg., 157: 175-179, 1989.
    OpenUrlCrossRefPubMed
  12. ↵
    Giardiello F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R., Offerhaus G. J. A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
    OpenUrlCrossRefPubMed
  13. ↵
    Nugent K. P., Farmer K. C. R., Spigelman A. D., Williams C. B., Phillips R. K. S. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg., 80: 1618-1619, 1993.
    OpenUrlPubMed
  14. ↵
    Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101: 635-639, 1991.
    OpenUrlPubMed
  15. ↵
    Wolfe M. M., Lichtenstein D. R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 340: 1888-1899, 1999.
    OpenUrlCrossRefPubMed
  16. ↵
    Taketo M. M. Cyclooxygenase-2 inhibitors in tumorigenesis. J. Natl. Cancer Inst., 90: 1609-1620, 1998.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M. Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
    OpenUrlCrossRefPubMed
  18. ↵
    Jacoby R. F., Seibert K., Cole C. E., Kelloff G., Lubet R. A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res., 60: 5040-5044, 2000.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Steinbach G., Lynch P. M., Phillips R. K. S., Wallace M. H., Hawk E., Gordon G. B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L-K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
    OpenUrlCrossRefPubMed
  20. ↵
    Chan C. C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A. W., Forrest M. J., Gauthier J. Y., Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O’neill G. P., Ouellet M., Patrick D., Percival M. D., Perrier H., Prasit P., Rodger I., Tagari P., Therien M., Vickers P., Visco D., Wang Z., Webb J., Wong E., Xu L-J., Young R. N., Zamboni R., Riendeau D. Rofecoxib [Vioxx. MK-0966; 4-(4′ - Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cycooxygenase-2 Inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther., 290: 551-560, 1999.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Oshima M., Murai (Hata) N., Kargman S., Arguello A., Luk P., Kwong E., Taketo M. M., Evans J. F. Chemoprevention of intestinal polyposis in the ApcΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res., 61: 1733-1740, 2001.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Oshima M., Taketo M. M. COX selectivity and animal models for colon cancer. Curr. Pharm. Des., 8: 1021-1034, 2002.
    OpenUrlCrossRefPubMed
  23. ↵
    Thomson J. P. S. Familial adenomatous polyposis: the large bowel. Ann. R. Coll. Surg. Engl., 72: 177-180, 1990.
    OpenUrlPubMed
  24. ↵
    Cannon G. W., Caldwell J. R., Holt P., McLean B., Seidenberg B., Bolognese J., Ehrich E., Mukhopadhyay S., Daniels B. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum., 43: 978-987, 2000.
    OpenUrlCrossRefPubMed
  25. ↵
    Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M. B., Hawkey C. J., Hochberg M. C., Kvien T. K., Schnitzer T. J. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N. Engl. J. Med., 343: 1520-1528, 2000.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 9 (13)
October 2003
Volume 9, Issue 13
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Rofecoxib, a Selective Cyclooxygenase-2 Inhibitor, on Rectal Polyps in Familial Adenomatous Polyposis Patients
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Rofecoxib, a Selective Cyclooxygenase-2 Inhibitor, on Rectal Polyps in Familial Adenomatous Polyposis Patients
Tetsuro Higuchi, Takeo Iwama, Keigo Yoshinaga, Masahiro Toyooka, Makoto M. Taketo and Kenichi Sugihara
Clin Cancer Res October 15 2003 (9) (13) 4756-4760;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Rofecoxib, a Selective Cyclooxygenase-2 Inhibitor, on Rectal Polyps in Familial Adenomatous Polyposis Patients
Tetsuro Higuchi, Takeo Iwama, Keigo Yoshinaga, Masahiro Toyooka, Makoto M. Taketo and Kenichi Sugihara
Clin Cancer Res October 15 2003 (9) (13) 4756-4760;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Regular Articles

  • Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer
  • Lactoferrin Down-Regulates G1 Cyclin-Dependent Kinases during Growth Arrest of Head and Neck Cancer Cells
  • ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy
Show more Regular Articles

Clinical Trials

  • Abstract B32: RADIANCE: An open-label, nonrandomized, prospective biomarker study to assess analytic concordance between noninvasive testing and tissue testing for EGFR T790M mutation detection in patients with non-small cell lung cancer
  • Abstract B33: Expansion study of pegylated arginine deiminase (ADI-PEG20), pemetrexed, and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer (TRAP)
  • Abstract B34: Safety and activity of the IL-15/sIL-15Rα complex ALT-803 in combination with the anti-PD1 mAb nivolumab in metastatic non-small cell lung cancer
Show more Clinical Trials
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement